The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
Stocks rose on Friday, but notched weekly losses as investors worried the U.S.-China trade war is hurting economic growth.US Marketsread more
The combination of mounting recession fears, bets on a more cautious Fed and a regular uptick in market volatility could spell more losses.Marketsread more
The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting 1 in every...Biotech and Pharmaceuticalsread more
SpaceX has raised just over $1 billion in financing since the beginning of the year.Investing in Spaceread more
An analyst for Ark Invest, which has a major investment in Tesla, says recent drastic price-target cuts by others on Wall Street are missing the big picture.Investingread more
A federal judge in California has blocked President Donald Trump from building sections of his long-sought border wall with money secured under his declaration of a national...Politicsread more
Former Foreign Minister Boris Johnson is seen as the bookmaker's favorite to succeed outgoing Prime Minister Theresa May.Europe Politicsread more
The race is underway to find a vaccine that can control African swine fever, a highly contagious and deadly viral infection ravaging China's hog population. There is currently...Agricultureread more
Apple bought Tueo Health, which was developing tech to help parents monitor asthma symptoms in children, using a mobile app and commercial breathing sensors.Technologyread more
The Senate Finance Committee on Tuesday grilled senior executives from seven of the largest pharmaceutical companies for raising the list price of prescription drugs in the U.S.
Sen. Ron Wyden, D-Ore, the ranking member on the committee, called out drug giant AbbVie for raising the price of its blockbuster rheumatoid arthritis drug Humira. He said the company doubled the price of a 12-month supply for the drug to $38,000 from $19,000 over the course of six years.
"Can the patients opt for a less expensive alternative? They can't, because AbbVie protects the exclusivity of Humira like Gollum with his ring. Thick cobwebs of patents and shadowy deals with drugmakers, all of them are in place to keep the cash flowing," Wyden said, referring to the slimy "Lord of the Rings" character who coveted the ring of power.
Executives of AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi were testifying before the committee at a hearing called "Drug Pricing in America: A Prescription for Change, Part II."
Sen. Debbie Stabenow, D-Mich., asked AbbVie CEO Richard Gonalez why the company doesn't offer the same price on its best-selling drug, Humira, to patients in the U.S. as it does overseas.
"Because Humira plays a very important role in AbbVie's overall funding of R&D," he said.
Congress and President Donald Trump's administration have made lowering drug prices one of their top priorities. The committee, led by Sen. Chuck Grassley, R-Iowa, argues that prescription drug costs, which totaled more than $333 billion in 2017, are too high and the pace of drug price increases is "unsustainable."
The pharma leaders criticized middlemen, including pharmacy benefit managers, for pocketing discounts instead of passing them along to patients. In written testimony submitted ahead of the hearing, the companies threw their support behind a number of Trump administration proposals and pitched some of their own ideas, including changes to Medicare.
But none of the seven drugmakers committed to, or even suggested, lowering the list prices of their drugs. Some referenced these prices as simply the price that's advertised, not what consumers actually pay.
AbbVie has nearly doubled the price since 2014 of Humira, which is used to treat arthritis, plaque psoriasis and Crohn's disease, among other diseases, according to a review of data provided by Rx Savings Solutions. The drug now carries a list price of more than $60,000 per year. Sanofi has increased the price of its long-acting insulin Lanctus 48 percent since 2014, according to data from Rx Savings Solutions.
The companies all agreed that public perception is taken into account when pricing drugs.
When asked whether they support a Trump administration proposal that would pass an estimated $29 billion in rebates paid to pharmacy benefit managers to consumers during the hearing, all the drugmakers said, "yes."
AstraZeneca CEO Pascal Soriot said he would "go a step further," saying, "if rebates were removed from the commercial sector as well, we would definitely reduce our list price."